These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28673022)

  • 1. Secondary prevention for screening detected rheumatic heart disease: opportunities to improve adherence.
    Engelman D; Ah Kee M; Mataika RL; Kado JH; Colquhoun SM; Tulloch J; Steer AC
    Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):154-162. PubMed ID: 28673022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to secondary antibiotic prophylaxis for patients with rheumatic heart disease diagnosed through screening in Fiji.
    Engelman D; Mataika RL; Kado JH; Ah Kee M; Donath S; Parks T; Steer AC
    Trop Med Int Health; 2016 Dec; 21(12):1583-1591. PubMed ID: 27730711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequate adherence to benzathine penicillin secondary prophylaxis following the diagnosis of rheumatic heart disease by echocardiographic screening.
    Culliford-Semmens N; Tilton E; Webb R; Lennon D; Paku B; Malcolm J; French S; Blair N; Wilson N
    N Z Med J; 2017 Jun; 130(1457):50-57. PubMed ID: 28617789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzathine penicillin adherence for secondary prophylaxis among patients affected with rheumatic heart disease attending Mulago Hospital.
    Musoke C; Mondo CK; Okello E; Zhang W; Kakande B; Nyakoojo W; Freers J
    Cardiovasc J Afr; 2013 May; 24(4):124-9. PubMed ID: 24217043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The personal and clinical impact of screen-detected maternal rheumatic heart disease in Uganda: a prospective follow up study.
    Voleti S; Okello E; Murali M; Sarnacki R; Majwala A; Ssembatya R; Bakka O; Namisanvu H; Njeri A; Matovu A; DeStigter K; Sable C; Beaton A
    BMC Pregnancy Childbirth; 2020 Oct; 20(1):611. PubMed ID: 33036571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative examination of secondary prophylaxis in rheumatic heart disease: factors influencing adherence to secondary prophylaxis in Uganda.
    Huck DM; Nalubwama H; Longenecker CT; Frank SH; Okello E; Webel AR
    Glob Heart; 2015 Mar; 10(1):63-69.e1. PubMed ID: 25754568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial.
    Beaton A; Okello E; Engelman D; Grobler A; Scheel A; DeWyer A; Sarnacki R; Omara IO; Rwebembera J; Sable C; Steer A
    Am Heart J; 2019 Sep; 215():95-105. PubMed ID: 31301533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach.
    Ralph AP; Fittock M; Schultz R; Thompson D; Dowden M; Clemens T; Parnaby MG; Clark M; McDonald MI; Edwards KN; Carapetis JR; Bailie RS
    BMC Health Serv Res; 2013 Dec; 13():525. PubMed ID: 24350582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial).
    Rwebembera J; Ndagire E; Carvalho N; Webel AR; Sable C; Okello E; Sarnacki R; Spaziani AM; Mucunguzi A; Engelman D; Grobler A; Steer A; Beaton A
    Am Heart J; 2024 Sep; 275():74-85. PubMed ID: 38797460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study.
    Belay W; Dessie A; Ahmed H; Gedlu E; Mariyo A; Shehibo A; Tigabu Z; Aliyu MH; Soslow J
    BMC Cardiovasc Disord; 2022 Feb; 22(1):26. PubMed ID: 35109807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to secondary prevention of rheumatic fever and rheumatic heart disease in young people: an 11-year retrospective study.
    Liaw J; Gorton S; Heal C; White A
    Aust N Z J Public Health; 2022 Dec; 46(6):758-763. PubMed ID: 35616403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.
    Wyber R; Boyd BJ; Colquhoun S; Currie BJ; Engel M; Kado J; Karthikeyan G; Sullivan M; Saxena A; Sheel M; Steer A; Mucumbitsi J; Zühlke L; Carapetis J
    Drug Deliv Transl Res; 2016 Oct; 6(5):572-8. PubMed ID: 27465618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
    Beaton A; Okello E; Rwebembera J; Grobler A; Engelman D; Alepere J; Canales L; Carapetis J; DeWyer A; Lwabi P; Mirabel M; Mocumbi AO; Murali M; Nakitto M; Ndagire E; Nunes MCP; Omara IO; Sarnacki R; Scheel A; Wilson N; Zimmerman M; Zühlke L; Karthikeyan G; Sable CA; Steer AC
    N Engl J Med; 2022 Jan; 386(3):230-240. PubMed ID: 34767321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic penicillin by the full moon: a novel approach in Central Australia that may help to reduce the risk of rheumatic heart disease.
    Kearns TM; Schultz R; McDonald V; Andrews RM
    Rural Remote Health; 2010; 10(3):1464. PubMed ID: 20795756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to Improving Adherence to Secondary Prophylaxis for Rheumatic Fever and Rheumatic Heart Disease: A Literature Review with a Global Perspective.
    Rémond MG; Coyle ME; Mills JE; Maguire GP
    Cardiol Rev; 2016; 24(2):94-8. PubMed ID: 25807106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever, Jamaica.
    Thompson SB; Brown CH; Edwards AM; Lindo JL
    Pathog Glob Health; 2014 Jul; 108(5):229-34. PubMed ID: 25113585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinic factors associated with better delivery of secondary prophylaxis in acute rheumatic fever management.
    Quinn E; Girgis S; Van Buskirk J; Matthews V; Ward JE
    Aust J Gen Pract; 2019 Dec; 48(12):859-865. PubMed ID: 31774991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sharing success - understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease.
    Chamberlain-Salaun J; Mills J; Kevat PM; Rémond MG; Maguire GP
    BMC Cardiovasc Disord; 2016 Aug; 16(1):166. PubMed ID: 27581750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence rates and risk factors for suboptimal adherence to secondary prophylaxis for rheumatic fever.
    Kevat PM; Gunnarsson R; Reeves BM; Ruben AR
    J Paediatr Child Health; 2021 Mar; 57(3):419-424. PubMed ID: 33340191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Delivery of Secondary Prophylaxis for Rheumatic Heart Disease in a High-Burden Setting: Outcome of a Stepped-Wedge, Community, Randomized Trial.
    Ralph AP; de Dassel JL; Kirby A; Read C; Mitchell AG; Maguire GP; Currie BJ; Bailie RS; Johnston V; Carapetis JR
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30018165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.